Search results
Results from the WOW.Com Content Network
Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital settings. The company is located in Parsippany, New Jersey. [1]
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...
NovoBiotic Pharmaceuticals owns the patent rights [3] to teixobactin, an antibiotic that has been shown to be active against pathogenic Gram-positive bacteria that have developed resistance to available approved antibiotics. The discovery and characterization of the compound was reported in 2015 in a collaboration between NovoBiotic ...
The approval of Appili's drug could help ease the metronidazole shortage in the U.S., especially for patients in hospitalized settings and those with severe i Canada's Appili gets US FDA approval ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small ...
Company Sales (USD millions/year) ∆ vs 2014 1 Adalimumab: Humira Biologic Rheumatoid arthritis: AbbVie Inc. 14,012 1,469 2 Ledipasvir/sofosbuvir: Harvoni Small molecule Hepatitis C: Gilead Sciences: 13,864 11,737 3 Etanercept: Enbrel Biologic Rheumatoid arthritis: Amgen. Pfizer. 8,697 4,009 4 Infliximab: Remicade Biologic Crohn's Disease ...
Ensitrelvir was approved for emergency use in Japan in November 2022, [9] [4] [5] before gaining full approval in March 2024. [1] It was approved in Singapore in November 2023. [17] In April 2023, ensitrelvir was given a "Fast Track" designation from the US Food and Drug Administration. [18]